

BIOTECHNOLOGY FUND

	SHARES	VALUE		SHARES	VALUE
COMMON STOCKS[†] - 99.6%					
BIOTECHNOLOGY - 73.0%					
Moderna, Inc.*	23,301	\$ 8,967,623			
Amgen, Inc.	39,753	8,453,475			
Gilead Sciences, Inc.	102,868	7,185,330			
Regeneron Pharmaceuticals, Inc.*	9,928	6,008,227			
Illumina, Inc.*	14,446	5,859,442			
Vertex Pharmaceuticals, Inc.*	29,015	5,263,031			
Biogen, Inc.*	17,162	4,856,674			
Seagen, Inc.*	26,887	4,565,413			
Corteva, Inc.	102,118	4,297,125			
Horizon Therapeutics plc*	35,498	3,888,451			
Alnylam Pharmaceuticals, Inc.*	19,289	3,641,956			
Bio-Rad Laboratories, Inc. — Class A*	4,782	3,567,133			
Royalty Pharma plc — Class A	96,425	3,484,800			
BioNTech SE ADR*	11,731	3,202,446			
Exact Sciences Corp.*	32,033	3,057,550			
BioMarin Pharmaceutical, Inc.*	37,808	2,922,180			
Incyte Corp.*	42,063	2,893,093			
Acceleron Pharma, Inc.*	16,696	2,873,382			
Novavax, Inc.*	13,798	2,860,463			
Guardant Health, Inc.*	22,085	2,760,846			
Mirati Therapeutics, Inc.*	13,717	2,426,674			
Biohaven Pharmaceutical Holding Company Ltd.*	16,918	2,350,079			
CRISPR Therapeutics AG*	20,768	2,324,562			
BeiGene Ltd. ADR*	5,937	2,155,131			
United Therapeutics Corp.*	11,346	2,094,245			
Exelixis, Inc.*	96,222	2,034,133			
Bridgebio Pharma, Inc.*	42,813	2,006,645			
Arrowhead Pharmaceuticals, Inc.*	31,567	1,970,728			
Blueprint Medicines Corp.*	18,681	1,920,594			
Zai Lab Ltd. ADR*	17,729	1,868,459			
Ultragenyx Pharmaceutical, Inc.*	20,667	1,863,957			
Halozyne Therapeutics, Inc.*	44,596	1,814,165			
TG Therapeutics, Inc.*	52,923	1,761,277			
Fate Therapeutics, Inc.*	29,703	1,760,497			
Twist Bioscience Corp.*	16,371	1,751,206			
Beam Therapeutics, Inc.*	19,917	1,732,978			
Pacific Biosciences of California, Inc.*	67,045	1,713,000			
Ionis Pharmaceuticals, Inc.*	48,709	1,633,700			
Iovance Biotherapeutics, Inc.*	62,568	1,542,927			
Arena Pharmaceuticals, Inc.*	24,861	1,480,473			
Cassava Sciences, Inc.* ¹	22,977	1,426,412			
Veracyte, Inc.*	30,413	1,412,684			
ACADIA Pharmaceuticals, Inc.*	77,561	1,288,288			
Apellis Pharmaceuticals, Inc.*	39,024	1,286,231			
Sage Therapeutics, Inc.*	28,082	1,244,313			
PTC Therapeutics, Inc.*	32,439	1,207,055			
Emergent BioSolutions, Inc.*	23,787	1,191,015			
Amicus Therapeutics, Inc.*	119,705	1,143,183			
Editas Medicine, Inc.*	26,056	1,070,380			
Global Blood Therapeutics, Inc.*	38,173	\$ 972,648			
Bluebird Bio, Inc.*	48,506	926,950			
Inovio Pharmaceuticals, Inc.* ¹	128,863	922,659			
ChemoCentryx, Inc.*	51,485	880,394			
Total Biotechnology					<u>143,786,282</u>
PHARMACEUTICALS - 16.3%					
AbbVie, Inc.	99,059	10,685,494			
AstraZeneca plc ADR	81,796	4,912,668			
Viatis, Inc.	229,847	3,114,427			
Jazz Pharmaceuticals plc*	23,220	3,023,476			
Neurocrine Biosciences, Inc.*	24,577	2,357,180			
Alkermes plc*	74,988	2,312,630			
Intellia Therapeutics, Inc.*	16,939	2,272,367			
Sarepta Therapeutics, Inc.*	23,645	2,186,690			
Pacira BioSciences, Inc.*	21,842	1,223,152			
Total Pharmaceuticals					<u>32,088,084</u>
HEALTHCARE-PRODUCTS - 5.7%					
Bio-Techne Corp.	6,666	3,230,144			
Novocure Ltd.*	21,720	2,523,212			
Natera, Inc.*	21,518	2,397,966			
Adaptive Biotechnologies Corp.*	46,439	1,578,462			
CareDx, Inc.*	21,579	1,367,461			
Total Healthcare-Products					<u>11,097,245</u>
HEALTHCARE-SERVICES - 4.6%					
ICON plc*	10,678	2,797,849			
Syneos Health, Inc.*	25,590	2,238,613			
Medpace Holdings, Inc.*	10,678	2,021,132			
Invitae Corp.* ¹	66,539	1,891,704			
Total Healthcare-Services					<u>8,949,298</u>
Total Common Stocks					<u>195,920,909</u>
(Cost \$117,500,720)					
				FACE	
				AMOUNT	
REPURCHASE AGREEMENTS^{††,2} - 0.5%					
J.P. Morgan Securities LLC					
issued 09/30/21 at 0.05%					
due 10/01/21			\$	592,217	592,217
BofA Securities, Inc.					
issued 09/30/21 at 0.02%					
due 10/01/21				230,106	230,106
Barclays Capital, Inc.					
issued 09/30/21 at 0.03%					
due 10/01/21				230,106	230,106
Total Repurchase Agreements					<u>1,052,429</u>
(Cost \$1,052,429)					

BIOTECHNOLOGY FUND

	SHARES	VALUE
SECURITIES LENDING COLLATERAL^{†,3} - 1.6%		
Money Market Fund		
First American Government Obligations Fund — Class Z, 0.02% ⁴	3,244,660	\$ 3,244,660
Total Securities Lending Collateral (Cost \$3,244,660)		<u>3,244,660</u>
Total Investments - 101.7% (Cost \$121,797,809)		<u>\$ 200,217,998</u>
Other Assets & Liabilities, net - (1.7)%		<u>(3,335,939)</u>
Total Net Assets - 100.0%		<u>\$ 196,882,059</u>

* Non-income producing security.

† Value determined based on Level 1 inputs.

†† Value determined based on Level 2 inputs.

¹ All or a portion of this security is on loan at September 30, 2021.

² Repurchase Agreements.

³ Securities lending collateral.

⁴ Rate indicated is the 7-day yield as of September 30, 2021.

ADR — American Depositary Receipt

plc — Public Limited Company